BCR and prostate cancer: Cheng et al. reported LVI to be an independent prognostic factor of BCR and cancer-specific survival for clinically localized prostate cancer patients, increasing BCR risk by 1.6 fold in their multivariate model (95% CI 1.12–2.38) [15].